AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Sunovion President and CEO Dr. Antony Loebel Receives Outstanding Leadership Award at CNS Summit

November 14, 2019 GMT
1 of 2
Sunovion President and CEO Dr. Antony Loebel Receives Outstanding Leadership Award at CNS Summit
1 of 2
Sunovion President and CEO Dr. Antony Loebel Receives Outstanding Leadership Award at CNS Summit

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Nov 14, 2019--

Sunovion Pharmaceuticals Inc. (Sunovion) today announced that Antony Loebel, M.D., President and Chief Executive Officer of Sunovion, received the Leadership Award during the recent CNS Summit. The award was presented to Dr. Loebel by Dr. Amir Kalali, Chairman and Chief Curator of CNS Summit.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191114005167/en/

Sunovion President and CEO Dr. Loebel Receiving Outstanding Leadership Award at the CNS Summit (Photo: Business Wire)

Dr. Kalali stated that Dr. Loebel was selected for this 2019 Leadership Award due to the impact on patients of so many clinical development programs led by him, that have resulted in new treatments for patients.

“I am deeply honored by this recognition, and further inspired to continue working towards treatment advances for people living with psychiatric and neurological disorders. Together, we can find ways to take advantage of rapidly emerging scientific understanding and focus on collaborative and innovative solutions for global health problems. This honor brings attention to the needs of people living with the serious health conditions we aim to treat,” said Antony Loebel, M.D., President and Chief Executive Officer, Sunovion Pharmaceuticals Inc.

Dr. Loebel has a track record of leading the successful development of new treatments for patients with brain disorders, as well as bringing new innovation to research and development. In 2015, he was recognized by the International Society for CNS Drug Development for his leadership in the field. Dr. Loebel was selected by PharmaVOICE in 2019 and 2013 as one of the “100 Most Inspiring People” in the pharmaceutical industry.

Dr. Loebel joined Sunovion in 2007. As Chief Medical Officer, he provided strategic direction and leadership of Research & Development (R&D), including overseeing the Global Clinical Development organization. In this role, he directed initiatives designed to improve global R&D operational efficiency and to address unmet medical needs through innovation in drug development.

Dr. Loebel is a board-certified psychiatrist, a Clinical Assistant Professor of Psychiatry at the New York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a member of the American College of Neuropsychopharmacology (ACNP). Dr. Loebel earned a M.D. from the University of Washington School of Medicine in Seattle.

About CNS Summit

Founded by R&D leaders, the CNS Summit is a community working collaboratively to shape the future of the life sciences. Celebrating the 10th Anniversary this year, CNS Summit 2019 took place Oct. 31 – Nov. 3, 2019 in Boca Raton, Florida. For more information, visit www.cnssummit.org.

About Sunovion Pharmaceuticals Inc. (Sunovion)

Sunovion is a global biopharmaceutical company focused on the innovative application of science and medicine to help people with serious medical conditions. Sunovion’s vision is to lead the way to a healthier world. The company’s spirit of innovation is driven by the conviction that scientific excellence paired with meaningful advocacy and relevant education can improve lives. With patients at the center of everything it does, Sunovion has charted new paths to life-transforming treatments that reflect ongoing investments in research and development and an unwavering commitment to support people with psychiatric, neurological and respiratory conditions.

Headquartered in Marlborough, Mass., Sunovion is an indirect, wholly-owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd. Sunovion Pharmaceuticals Europe Ltd., based in London, England, and Sunovion Pharmaceuticals Canada Inc., based in Mississauga, Ontario, are wholly-owned direct subsidiaries of Sunovion Pharmaceuticals Inc. Additional information can be found on the company’s websites: www.sunovion.com, www.sunovion.eu and www.sunovion.ca. Connect with Sunovion on Twitter, LinkedIn, Facebook and YouTube.

© 2019 Sunovion Pharmaceuticals Inc. All rights reserved.

For a copy of this release, visit Sunovion’s web site at www.sunovion.com

View source version on businesswire.com:https://www.businesswire.com/news/home/20191114005167/en/

CONTACT: Jennifer Baird

Senior Director, Corporate Communications

Sunovion Pharmaceuticals Inc.

508-787-4109

jennifer.baird@sunovion.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: BIOTECHNOLOGY PHARMACEUTICAL HEALTH

SOURCE: Sunovion Pharmaceuticals Inc.

Copyright Business Wire 2019.

PUB: 11/14/2019 09:00 AM/DISC: 11/14/2019 09:01 AM

http://www.businesswire.com/news/home/20191114005167/en